Skip to main content
. Author manuscript; available in PMC: 2015 Sep 1.
Published in final edited form as: Hum Pathol. 2014 Jun 5;45(9):1893–1899. doi: 10.1016/j.humpath.2014.05.011

Figure 4. Comparison of Serum GP88 levels in Stage IIIb/IV NSCLC and non-lung cancer control subjects.

Figure 4

Serum was collected from Stage IIIb/IV NSCLC (n=19) and control subjects that did not have lung cancer (n=20). Serum GP88 levels was determined by sandwich EIA as described in the method section.